interstitial cystitis

IC/BPS: One-fourth of patients have Hunner lesionsAbout one-fourth of patients with interstitial cystitis/bladder pain syndrome have Hunner lesions in the bladder visible on cystoscopy.
Repeat hydrodistention found safe in treating ICRepeated hydrodistention as therapy for interstitial cystitis has a low complication rate and does not decrease bladder capacity over time.
Uro Pipeline: Supplemental application submitted for advanced RCC treatmentOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Older drug, versatile clinicians may help IC/PBS patients“It may be that urologists need to rely more on their internal medicine instincts to find new ways to treat conditions such as IC/PBS,” writes SUNA President Gwendolyn Hooper, PhD, APRN.
Cyclosporine shows efficacy in refractory IC patientsOral cyclosporine can offer a safe and effective treatment option for refractory interstitial, even in patients who have been on chronic narcotic medications and particularly in those with Hunner’s lesions, according to the findings of a study presented by Cleveland Clinic urologists at the 2016 AUA annual meeting in San Diego.
The future of drug delivery in the bladder?
Device efficacious for treating IC with Hunner’s lesionsA novel lidocaine-releasing intravesical system (LiRIS, Allergan) demonstrated promising efficacy and safety in a small proof-of-concept study investigating its use as a treatment for women suffering from interstitial cystitis with Hunner’s lesions, reported Kenneth M. Peters, MD, at the AUA annual meeting in San Diego.
Interstitial cystitis: Simplified diagnosis and treatment
Interstitial cystitis: Simplified diagnosis and treatmentInterstitial cystitis/bladder pain syndrome (IC/BPS) is now recognized as a common etiology in women with chronic pelvic pain.
AUA 2016: Experts offer guidance on the meetingTo guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
Botulinum reduces pain in interstitial cystitis, BPSIntravesical onabotulinumtoxinA (Botox) reduces bladder pain in patients with interstitial cystitis/bladder pain syndrome (IC/BPS), two separate studies show.